Prof. Ian Meredith to Join Boston Scientific as Global Chief Medical Officer

October 10, 2016—Boston Scientific Corporation announced that Professor Ian Meredith, MBBS (Hons), PhD, AM (Member of the Order of Australia), will join the company as Executive Vice President and Global Chief Medical Officer in January 2017. Prof. Meredith currently serves as Professor of Medicine and Cardiology for Monash University, Director of MonashHeart and Monash Health and Executive Director of the Monash Cardiovascular Research Center in Melbourne, Australia.

In his new position, Prof. Meredith will lead clinical and medical affairs across Boston Scientific and will provide global leadership of the company's clinical trial strategy. He will succeed Executive Vice President and Global Chief Medical Officer Keith Dawkins, MD, who has announced his intention to retire from the company in January 2017.

Professor Meredith's work has focused on the development and clinical evaluation of devices for the treatment of coronary artery and structural heart disease, and he has been at the forefront of emerging percutaneous cardiac valve therapies. He served as the Global Principal Investigator of the REPRISE research program for Boston Scientific’s Lotus valve for transcatheter aortic valve replacement.

In Boston Scientific’s announcement, Chairman and Chief Executive Officer Mike Mahoney commented, “Ian is one of the world’s leading cardiac device clinical investigators and he has been an advisor to Boston Scientific for many years. His strong relationships within the global research and clinical community and his track record applying novel technologies to advance science and care for patients make him ideally suited to drive innovation and succeed Keith in this role. We are delighted that he will be joining our team.”

Prof. Meredith stated, “Boston Scientific has demonstrated a commitment to delivering meaningful innovation, and I look forward to joining the team to further develop the technology pipeline and deliver solutions for patients worldwide.”

According to Boston Scientific, Prof. Meredith has more than 25 years of experience as a clinical and interventional cardiologist. He has performed more than 10,000 invasive cardiac and coronary procedures, published more than 300 manuscripts, and has been Chief or Principal Investigator on 30 major international multicenter trials, including first-in-man trials of new drug-eluting stents.

After receiving undergraduate and doctorate degrees from Monash University, Prof. Meredith trained in Melbourne and completed his PhD at the Baker Institute. For 3 years, he was at the Brigham & Women’s Hospital and Harvard Medical School in Boston, Massachusetts, where he trained in interventional cardiology.